Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com.
Bone Therapeutics is a leading biotechnology company specializing in the development of cell therapy products for orthopaedics and bone diseases.
Its unique technology allows to produce biologically active bone cells that are able to regenerate a healthy bone environment and promote bone regeneration.
The product candidates have been developed for the treatment of indications with high unmet medical needs such as degenerative diseases of the spine, severe unhealed fractures and osteonecrosis of the hip.
The products, administrable through a minimally invasive percutaneous approach without open surgery, do not require long hospitalization, have already shown encouraging clinical results and address important unmet medical needs.
The Research Foundation – Flanders (FWO) is the agency that supports ground-breaking fundamental and strategic research at the universities of the Flemish Community. The FWO also stimulates cooperation between the Flemish universities and other research institutes.
High-performance scientific instruments and analytical and diagnostic solutions to explore life and materials at molecular level.